Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Research & Development (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Research & Development for 5 consecutive years, with $34.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 1.72% year-over-year to $34.6 million, compared with a TTM value of $91.5 million through Dec 2025, down 18.0%, and an annual FY2025 reading of $96.9 million, down 13.23% over the prior year.
  • Research & Development was $34.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $24.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $35.2 million in Q4 2024 and bottomed at $13.8 million in Q2 2022.
  • Average Research & Development over 5 years is $22.2 million, with a median of $22.3 million recorded in 2022.
  • The sharpest move saw Research & Development plummeted 47.54% in 2022, then surged 75.62% in 2024.
  • Year by year, Research & Development stood at $27.4 million in 2021, then tumbled by 47.54% to $14.4 million in 2022, then surged by 39.35% to $20.1 million in 2023, then skyrocketed by 75.62% to $35.2 million in 2024, then decreased by 1.72% to $34.6 million in 2025.
  • Business Quant data shows Research & Development for KNSA at $34.6 million in Q4 2025, $24.2 million in Q3 2025, and $18.8 million in Q2 2025.